The June issue of this newsletter traditionally is the last before a summer hiatus for the VOICE in July and August. The year 2019 was, however, the only year in recent memory when we were able to stick to this plan. In all other years, we had to issue the newsletter in at least one of the two hypothetical hiatus months because urgent news had to be communicated to our readership. As of this point, we plan on being in touch again in September with a first issue of the VOICE in the new academic year 2020/2021. Considering the strange world we are living in, however, we would not be surprised if our summer vacation this year will again be interrupted.
In the meantime, we wish all of our patients, ex-patients, colleagues and other readers a wonderful summer. We very much hope that by September our world will have mostly normalized. CHR, as in all prior years, does not take a summer break since our summer months have always been especially busy. As we are already witnessing a rapid increase in treatment cycle starts, we anticipate that this increase will continue into the summer month.
Continuing our discussion on COVID-19, we in this issue of the VOICE address a relatively new phrase that in recent weeks and months has entered our consciousness due to the pandemic, “to follow science.” We also continue our article series on how to individualize treatment of women with low functional ovarian reserve with Volume II on individualized treatments for women with LFOR.
Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.
DISCOVER YOUR TREATMENT OPTIONS
